SrasV1, Ncbi, Merge, bibRecord, 002144

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Identifieur interne : 002144 ( Ncbi/Merge ); précédent : 002143; suivant : 002145

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Auteurs : R. Ramajayam [Taïwan] ; Kian-Pin Tan ; Hun-Ge Liu ; Po-Huang Liang

Source :

Bioorganic & medicinal chemistry letters [ 1464-3405 ] ; 2010.

RBID : pubmed:20494577

Descripteurs français

KwdFr :
- Concentration inhibitrice 50, Cysteine endopeptidases, Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (synthèse chimique), Liaison aux protéines, Modèles moléculaires, Protéines virales (antagonistes et inhibiteurs), Pyrimidines (pharmacologie), Pyrimidines (synthèse chimique), Relation structure-activité, Simulation numérique, Virus du SRAS (), Virus du SRAS (enzymologie).
MESH :
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Virus du SRAS.
- pharmacologie : Inhibiteurs de protéases, Pyrimidines.
- synthèse chimique : Inhibiteurs de protéases, Pyrimidines.
- Concentration inhibitrice 50, Cysteine endopeptidases, Liaison aux protéines, Modèles moléculaires, Relation structure-activité, Simulation numérique, Virus du SRAS.

English descriptors

KwdEn :
- Computer Simulation, Cysteine Endopeptidases, Inhibitory Concentration 50, Models, Molecular, Protease Inhibitors (chemical synthesis), Protease Inhibitors (pharmacology), Protein Binding, Pyrimidines (chemical synthesis), Pyrimidines (pharmacology), SARS Virus (drug effects), SARS Virus (enzymology), Structure-Activity Relationship, Viral Proteins (antagonists & inhibitors).
MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemical synthesis : Protease Inhibitors, Pyrimidines.
- chemical , pharmacology : Protease Inhibitors, Pyrimidines.
- chemical : Cysteine Endopeptidases.
- drug effects : SARS Virus.
- enzymology : SARS Virus.
- Computer Simulation, Inhibitory Concentration 50, Models, Molecular, Protein Binding, Structure-Activity Relationship.

Abstract

A series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Two candidates had encouraging results for the development of new anti-SARS compounds.

DOI: 10.1016/j.bmcl.2010.04.118
PubMed: 20494577

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001692
to stream PubMed, to step Curation: 001692
to stream PubMed, to step Checkpoint: 001580

Links to Exploration step

pubmed:20494577

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.</title>
<author><name sortKey="Ramajayam, R" sort="Ramajayam, R" uniqKey="Ramajayam R" first="R" last="Ramajayam">R. Ramajayam</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Biological Chemistry, Academia Sinica, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tan, Kian Pin" sort="Tan, Kian Pin" uniqKey="Tan K" first="Kian-Pin" last="Tan">Kian-Pin Tan</name>
</author>
<author><name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20494577</idno>
<idno type="pmid">20494577</idno>
<idno type="doi">10.1016/j.bmcl.2010.04.118</idno>
<idno type="wicri:Area/PubMed/Corpus">001692</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001692</idno>
<idno type="wicri:Area/PubMed/Curation">001692</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001692</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001580</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001580</idno>
<idno type="wicri:Area/Ncbi/Merge">002144</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.</title>
<author><name sortKey="Ramajayam, R" sort="Ramajayam, R" uniqKey="Ramajayam R" first="R" last="Ramajayam">R. Ramajayam</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Institute of Biological Chemistry, Academia Sinica, Taipei</wicri:regionArea>
<wicri:noRegion>Taipei</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tan, Kian Pin" sort="Tan, Kian Pin" uniqKey="Tan K" first="Kian-Pin" last="Tan">Kian-Pin Tan</name>
</author>
<author><name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</analytic>
<series><title level="j">Bioorganic & medicinal chemistry letters</title>
<idno type="eISSN">1464-3405</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Computer Simulation</term>
<term>Cysteine Endopeptidases</term>
<term>Inhibitory Concentration 50</term>
<term>Models, Molecular</term>
<term>Protease Inhibitors (chemical synthesis)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protein Binding</term>
<term>Pyrimidines (chemical synthesis)</term>
<term>Pyrimidines (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (enzymology)</term>
<term>Structure-Activity Relationship</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Concentration inhibitrice 50</term>
<term>Cysteine endopeptidases</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Inhibiteurs de protéases (synthèse chimique)</term>
<term>Liaison aux protéines</term>
<term>Modèles moléculaires</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Pyrimidines (pharmacologie)</term>
<term>Pyrimidines (synthèse chimique)</term>
<term>Relation structure-activité</term>
<term>Simulation numérique</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (enzymologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Protease Inhibitors</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Cysteine Endopeptidases</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Inhibiteurs de protéases</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Computer Simulation</term>
<term>Inhibitory Concentration 50</term>
<term>Models, Molecular</term>
<term>Protein Binding</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Concentration inhibitrice 50</term>
<term>Cysteine endopeptidases</term>
<term>Liaison aux protéines</term>
<term>Modèles moléculaires</term>
<term>Relation structure-activité</term>
<term>Simulation numérique</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Two candidates had encouraging results for the development of new anti-SARS compounds.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20494577</PMID>
<DateCompleted><Year>2010</Year>
<Month>09</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3405</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>20</Volume>
<Issue>12</Issue>
<PubDate><Year>2010</Year>
<Month>Jun</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Bioorganic & medicinal chemistry letters</Title>
<ISOAbbreviation>Bioorg. Med. Chem. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.</ArticleTitle>
<Pagination><MedlinePgn>3569-72</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2010.04.118</ELocationID>
<Abstract><AbstractText>A series of 2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine as SARS-CoV 3CL protease inhibitors were developed and their potency was evaluated by in vitro protease inhibitory assays. Two candidates had encouraging results for the development of new anti-SARS compounds.</AbstractText>
<CopyrightInformation>Copyright 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramajayam</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Kian-Pin</ForeName>
<Initials>KP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Hun-Ge</ForeName>
<Initials>HG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Po-Huang</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>05</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Bioorg Med Chem Lett</MedlineTA>
<NlmUniqueID>9107377</NlmUniqueID>
<ISSNLinking>0960-894X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year>
<Month>03</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2010</Year>
<Month>04</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2010</Year>
<Month>04</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20494577</ArticleId>
<ArticleId IdType="pii">S0960-894X(10)00596-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.bmcl.2010.04.118</ArticleId>
<ArticleId IdType="pmc">PMC7126861</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol Drug Des. 2008 Jul;72(1):34-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18611220</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chembiochem. 2007 Sep 24;8(14):1654-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17722121</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol. 2006 Mar;13(3):261-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16638531</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2005 Nov 3;48(22):6832-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16250642</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2004 May 4;43(17):4906-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15109248</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2005 Jun 30;48(13):4469-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15974598</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Chem Inf Model. 2005 Jan-Feb;45(1):10-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15667124</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19362479</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Sep 10;574(1-3):116-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15358550</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):862-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15147951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol. 2004 Sep;11(9):1293-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15380189</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18827378</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol. 2004 Oct;11(10):1445-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15489171</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2005 Jun 15;15(12):3058-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15896959</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2009 Feb 4;583(3):549-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19166843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2005 Nov 3;48(22):6767-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16250632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2005 Sep 1;13(17):5240-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15994085</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2007 Nov 1;17(21):5876-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17855091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2004 Dec 2;47(25):6113-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15566280</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Jun;79(11):7095-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15890949</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Taïwan</li>
</country>
</list>
<tree><noCountry><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
<name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
<name sortKey="Tan, Kian Pin" sort="Tan, Kian Pin" uniqKey="Tan K" first="Kian-Pin" last="Tan">Kian-Pin Tan</name>
</noCountry>
<country name="Taïwan"><noRegion><name sortKey="Ramajayam, R" sort="Ramajayam, R" uniqKey="Ramajayam R" first="R" last="Ramajayam">R. Ramajayam</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002144 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002144 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:20494577
   |texte=   Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:20494577" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki